FirstWord

The latest measures include $1 billion in productivity savings, as well as $1.5 billion from the next phase of its manufacturing optimisation programme.

The pharma will discontinue development of tulisokibart in systemic sclerosis-associated interstitial lung disease.

The oral factor XIa inhibitor is under review in the EU, but concerns over Germany's recent healthcare reforms increase uncertainty over its launch.

Revenue this year is now expected to fall between $66.3 billion and $67.3 billion, up from a prior range of $65.8 billion to $67 billion.

The AI biotech secured ex-China rights to Alphamab's TROP2/HER3 ADC in a deal worth up to $2.2 billion and partnered with AstraZeneca on a breast cancer PROTAC programme.

Analyses of long-term TRUST-I and TRUST-II data will examine consistency of efficacy across key patient subgroupsNEW YORK, Aug. 4, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncolog...

TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase ...

University of Colorado Anschutz-led study shows automated oxygen system increases time in target oxygen range and reduces clinician workload compared with standard careAURORA, Colo., Aug. 3, 2026 /PRN...

– Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) –– Company raises 2026 revenue guidance –– Prepared to launch Ziihera® in HER2+ 1L GEA immediately following FD...

While AbbVie's oncology strategy gets notably less attention than its flagship immunology portfolio, on its recent earnings call, executives highlighted key ADCs that the pharma is leaning on as it continues to build out its post-Humira pipeline.